The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...

Loan originations are being used as a high-yield complement to the core property portfolio, specifically targeting ...

Investigational treatment improves outcomes without complete complement blockade ...

Commercial Loan Portfolio -- $160.4 million at quarter-end with a weighted average current yield, including paid-in-kind (PIK ...

Telecom infrastructure operations to contribute over $1 million in annualized revenue* 50 million AXXA shares canceled; Approx. 80 million canceled since March 2026* EXXE projects FY2026 revenue of ...

Q1 2026 Earnings Call April 23, 2026 8:30 AM EDTCompany ParticipantsJoshua Dicker - Executive VP, General Counsel & ...

They say the sector supports low income workers, generates billions of ringgit for the economy, and helps curb the brain ...

Good morning, and thank you for joining us today for The Hartford's First Quarter 2026 Earnings Call and Webcast. Yesterda ...

A workshop by GEOTHERMICA highlighted strategies and showcase projects that strengthen the case for scaling low-temperature ...

As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential ...

For the fifth consecutive year, trading activity in short-dated commodity options has set a new record. In 2025, the total average daily volume (ADV) for weekly options reached 79 ...

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...